{
  "data": [
    {
      "paragraphs": [
        {
          "qas": [
            {
              "id": "5a8dc57ffcd1d6a10c000025_001",
              "question": "Are the human bombesin receptors, GRPR and NMBR, frequently overexpressed G-protein-coupled-receptors by lung-cancers?"
            }
          ],
          "context": "Members of the gastrin-releasing peptide (GRP) family and its analogs bombesin (BBN) have been implicated in the biology of several human cancers including prostate, breast, colon and lung."
        },
        {
          "qas": [
            {
              "id": "5a8dc57ffcd1d6a10c000025_002",
              "question": "Are the human bombesin receptors, GRPR and NMBR, frequently overexpressed G-protein-coupled-receptors by lung-cancers?"
            }
          ],
          "context": "All 3 bombesin receptor subtypes (GRPR, NMBR, and BRS-3) were present on pulmonary and intestinal carcinoids by immunohistochemistry"
        },
        {
          "qas": [
            {
              "id": "5a8dc57ffcd1d6a10c000025_003",
              "question": "Are the human bombesin receptors, GRPR and NMBR, frequently overexpressed G-protein-coupled-receptors by lung-cancers?"
            }
          ],
          "context": "There is increased interest in the Bn-receptor family because they are frequently over/ectopically expressed by tumors and thus useful as targets for imaging or receptor-targeted-cytotoxicity. "
        },
        {
          "qas": [
            {
              "id": "5a76080683b0d9ea66000015_001",
              "question": "Is cilengitide effective for treatment of glioblastoma?"
            }
          ],
          "context": "RESULTS: fourteen randomized clinical trials were identified (7 with bevacizumab, 2 cilengitide, 1 enzastaurin, 1 dasatinib, 1 vandetanib, 1 temsirolimus, 1 cediranib) including 4330 patients. Antiangiogenic drugs showed no improvement in overall survival with a pooled HR of 1.00, a trend for an inferior outcome, in terms of overall survival, was observed in the group of patients receiving antiangiogenic drug alone compared to cytotoxic drug alone (HR=1.24, p=0.056)."
        },
        {
          "qas": [
            {
              "id": "5a76080683b0d9ea66000015_002",
              "question": "Is cilengitide effective for treatment of glioblastoma?"
            }
          ],
          "context": "However, we could not conclusively confirm whether cilengitide 2000mg/5/week was the optimum regime, as only one trial using this protocol was included in our study."
        },
        {
          "qas": [
            {
              "id": "5a76080683b0d9ea66000015_003",
              "question": "Is cilengitide effective for treatment of glioblastoma?"
            }
          ],
          "context": "Cilengitide (CGT) is a cyclic pentapeptide that demonstrated efficacy for GBM treatment by targeting the integrins av\u03b23 and av\u03b25 over-expressed on GBM cells."
        },
        {
          "qas": [
            {
              "id": "5a76080683b0d9ea66000015_004",
              "question": "Is cilengitide effective for treatment of glioblastoma?"
            }
          ],
          "context": "Cilengitide is recently failed in Phase III CENTRIC trial in unselected patients with GBM."
        },
        {
          "qas": [
            {
              "id": "5a76080683b0d9ea66000015_005",
              "question": "Is cilengitide effective for treatment of glioblastoma?"
            }
          ],
          "context": "In conclusion, we demonstrate that EGFRvIII/integrin \u03b23 complexes promote GBM progression and metastasis in the environment of hypoxia and vitronectin-enrichment, and cilengitide may serve as a promising therapeutics for EGFRvIII-positive GBMs."
        },
        {
          "qas": [
            {
              "id": "5a76080683b0d9ea66000015_006",
              "question": "Is cilengitide effective for treatment of glioblastoma?"
            }
          ],
          "context": "he addition of molecularly targeted drugs to TEM\u2009+\u2009RAD did not improve the OS of patients with GBM; however, it did improve PFS in patients treated by cilengitide who could not get improvement in OS. "
        },
        {
          "qas": [
            {
              "id": "5a76080683b0d9ea66000015_007",
              "question": "Is cilengitide effective for treatment of glioblastoma?"
            }
          ],
          "context": " The randomized phase III CENTRIC and phase II CORE trials explored the integrin inhibitor cilengitide in patients with newly diagnosed glioblastoma with versus without O6-methylguanine DNA methyltransferase (MGMT) promoter methylation. These trials failed to meet their primary endpoints"
        },
        {
          "qas": [
            {
              "id": "5a76080683b0d9ea66000015_008",
              "question": "Is cilengitide effective for treatment of glioblastoma?"
            }
          ],
          "context": ". In CORE, higher \u03b1v\u03b23 levels in tumor cells were associated with improved progression-free survival by central review and with improved overall survival in patients treated with cilengitide."
        },
        {
          "qas": [
            {
              "id": "5a76080683b0d9ea66000015_009",
              "question": "Is cilengitide effective for treatment of glioblastoma?"
            }
          ],
          "context": "Cilengitide combined with metronomic temozolomide and procarbazine in MGMT-promoter unmethylated glioblastoma did not improve survival compared with historical data and does not warrant further investigation."
        },
        {
          "qas": [
            {
              "id": "5a76016683b0d9ea6600000d_001",
              "question": "Down's syndrome occurs when an individual has an extra copy or part of a copy of chromosome 21, yes or no?"
            }
          ],
          "context": "Down syndrome (DS; trisomy 21) is the most common survivable disorder due to aneuploidy."
        },
        {
          "qas": [
            {
              "id": "5a76016683b0d9ea6600000d_002",
              "question": "Down's syndrome occurs when an individual has an extra copy or part of a copy of chromosome 21, yes or no?"
            }
          ],
          "context": "Down syndrome (DS), trisomy 21, is caused by increased dose of genes present on human chromosome 21 (HSA21)"
        },
        {
          "qas": [
            {
              "id": "5a76016683b0d9ea6600000d_003",
              "question": "Down's syndrome occurs when an individual has an extra copy or part of a copy of chromosome 21, yes or no?"
            }
          ],
          "context": "Down syndrome, or Trisomy 21, is the most frequently occurring chromosomal abnormality in live-born children. "
        },
        {
          "qas": [
            {
              "id": "5a76016683b0d9ea6600000d_004",
              "question": "Down's syndrome occurs when an individual has an extra copy or part of a copy of chromosome 21, yes or no?"
            }
          ],
          "context": "Down syndrome (DS), caused by trisomy of chromosome 21,"
        },
        {
          "qas": [
            {
              "id": "5a7615af83b0d9ea6600001f_001",
              "question": "Is vorinostat effective for glioblastoma?"
            }
          ],
          "context": "Conclusions: Vorinostat combined with standard chemoradiation had acceptable tolerability in newly diagnosed glioblastoma. Although the primary efficacy endpoint was not met, vorinostat sensitivity and resistance signatures could facilitate patient selection in future trials."
        },
        {
          "qas": [
            {
              "id": "5a7615af83b0d9ea6600001f_002",
              "question": "Is vorinostat effective for glioblastoma?"
            }
          ],
          "context": "LESSONS LEARNED: Combination regimen with bevacizumab (BEV) and vorinostat is well tolerated in patients with recurrent glioblastoma."
        },
        {
          "qas": [
            {
              "id": "5a7615af83b0d9ea6600001f_003",
              "question": "Is vorinostat effective for glioblastoma?"
            }
          ],
          "context": "CONCLUSION: Combination treatment of BEV and VOR was well tolerated. This combination therapy for this study population did not improve PFS6 or median OS when compared with BEV monotherapy."
        },
        {
          "qas": [
            {
              "id": "5a7615af83b0d9ea6600001f_004",
              "question": "Is vorinostat effective for glioblastoma?"
            }
          ],
          "context": "We present two patients with glioblastoma multiforme who developed severe hemolytic anemia shortly after initiating therapy with vorinostat, a pan-active histone deacetylase inhibitor, while on prophylactic dapsone."
        },
        {
          "qas": [
            {
              "id": "5a7615af83b0d9ea6600001f_005",
              "question": "Is vorinostat effective for glioblastoma?"
            }
          ],
          "context": "Vorinostat is the most advanced HDAC inhibitor that entered clinical trials in glioblastoma, showing activity in recurrent disease. Multiple phase II trials with vorinostat in combination with targeted agents, temozolomide and radiotherapy are currently recruiting. "
        },
        {
          "qas": [
            {
              "id": "5a7615af83b0d9ea6600001f_006",
              "question": "Is vorinostat effective for glioblastoma?"
            }
          ],
          "context": ". On the basis of the results of this phase II study, further evaluation of the vorinostat-bortezomib combination in GBM patients in this dose and schedule is not recommended."
        },
        {
          "qas": [
            {
              "id": "5a7615af83b0d9ea6600001f_007",
              "question": "Is vorinostat effective for glioblastoma?"
            }
          ],
          "context": "ith the increased toxicities associated with CPT-11 coupled with its unclear clinical significance, investigating the efficacy of vorinostat combined with bevacizumab alone may represent a more promising strategy to evaluate in the context of a phase II clinical trial."
        },
        {
          "qas": [
            {
              "id": "5a7615af83b0d9ea6600001f_008",
              "question": "Is vorinostat effective for glioblastoma?"
            }
          ],
          "context": "CONCLUSION: Vorinostat in combination with temozolomide is well tolerated in patients with HGG. A phase I/II trial of vorinostat with radiotherapy and concomitant TMZ in newly diagnosed glioblastoma is underway."
        },
        {
          "qas": [
            {
              "id": "5a773c50faa1ab7d2e000002_001",
              "question": "Has ATF4 transcription factor been linked to cancer and neoplastic transformation?"
            }
          ],
          "context": "aken together, we discovered a novel axis of BCL10-regulated OSCC progression via STAT1/ATF4/S100P/P65 signaling, which could predict the prognosis of OSCC and will be beneficial for developing therapeutic strategy against advanced OSCC"
        },
        {
          "qas": [
            {
              "id": "5a773c50faa1ab7d2e000002_002",
              "question": "Has ATF4 transcription factor been linked to cancer and neoplastic transformation?"
            }
          ],
          "context": "s a result, the level of phosphorylated Eukaryotic Initiation Factor 2 alpha (eIF2\u03b1) is markedly elevated, resulting in the promotion of a pro-adaptive signaling pathway by the inhibition of global protein synthesis and selective translation of Activating Transcription Factor 4 (ATF4). "
        },
        {
          "qas": [
            {
              "id": "5a773c50faa1ab7d2e000002_003",
              "question": "Has ATF4 transcription factor been linked to cancer and neoplastic transformation?"
            }
          ],
          "context": "Many cancers overexpress ATF4, a stress-induced transcription factor that promotes cell survival under hypoxic conditions and other stresses of the tumor microenvironment, but the potential contributions of ATF4 to oncogenesis itself have been little explored. Here, we report that ATF4 promotes oncogene-induced neoplastic transformation by suppressing the expression of cellular senescence-associated genes. "
        },
        {
          "qas": [
            {
              "id": "5a68eabab750ff4455000015_001",
              "question": "Is there an association between Klinefelter syndrome and breast cancer?"
            }
          ],
          "context": "Screening for breast cancer in male-to-female transsexuals should be undertaken for those with additional risk factors (e.g., family history, BRCA2 mutation, Klinefelter syndrome) and should be available to those who desire screening, preferably in a clinical trial."
        },
        {
          "qas": [
            {
              "id": "5a68eabab750ff4455000015_002",
              "question": "Is there an association between Klinefelter syndrome and breast cancer?"
            }
          ],
          "context": "Klinefelter syndrome (OR = 24.7; 95% CI = 8.94 to 68.4) and gynecomastia (OR = 9.78; 95% CI = 7.52 to 12.7) were also statistically significantly associated with risk, relations that were independent of BMI. "
        },
        {
          "qas": [
            {
              "id": "5a68eabab750ff4455000015_003",
              "question": "Is there an association between Klinefelter syndrome and breast cancer?"
            }
          ],
          "context": "Male breast cancer risk factors show strong association with BRCA2 mutations, as well as Klinefelter syndrome. "
        },
        {
          "qas": [
            {
              "id": "5a68eabab750ff4455000015_004",
              "question": "Is there an association between Klinefelter syndrome and breast cancer?"
            }
          ],
          "context": "The main risk factors include: the mutation of genes BRCA 1 and 2, Klinefelter's syndrome, alcohol, liver disease, obesity. "
        },
        {
          "qas": [
            {
              "id": "5a68eabab750ff4455000015_005",
              "question": "Is there an association between Klinefelter syndrome and breast cancer?"
            }
          ],
          "context": "Although aetiology is still unclear, constitutional, environmental, hormonal (abnormalities in estrogen/androgen balance) and genetic (positive family history, Klinefelter syndrome, mutations in BRCA1 and specially BRCA2) risk factors are already known. "
        },
        {
          "qas": [
            {
              "id": "5a68eabab750ff4455000015_006",
              "question": "Is there an association between Klinefelter syndrome and breast cancer?"
            }
          ],
          "context": "The largest study found 19.2- and 57.8-fold increases in incidence and mortality, respectively, with particularly high risks among 47,XXY mosaics. "
        },
        {
          "qas": [
            {
              "id": "5a68eabab750ff4455000015_007",
              "question": "Is there an association between Klinefelter syndrome and breast cancer?"
            }
          ],
          "context": "CONCLUSIONS: Additional well-designed epidemiologic studies are needed to clarify which patients with KS are at a high risk of developing MBC and to distinguish between possible predisposing factors, including altered endogenous hormones."
        },
        {
          "qas": [
            {
              "id": "5a68eabab750ff4455000015_008",
              "question": "Is there an association between Klinefelter syndrome and breast cancer?"
            }
          ],
          "context": "Major risk factors for developing male BC include clinical disorders involving hormonal imbalances (excess of estrogen or a deficiency of testosterone as seen in patients with Klinefelter syndrome) and a positive family history for breast cancer. "
        },
        {
          "qas": [
            {
              "id": "5a68eabab750ff4455000015_009",
              "question": "Is there an association between Klinefelter syndrome and breast cancer?"
            }
          ],
          "context": "Patients with 47, XXY karyotype (Klinefelter syndrome) appear to have increased risk of developing cancer, especially male breast cancer, germ cell tumours and non Hodgkin lymphomas, but rarely acute myeloid leukaemia. "
        },
        {
          "qas": [
            {
              "id": "5a6d186db750ff4455000031_001",
              "question": "Is there any role of Dlx1 and Dlx2 transcription factors in cortical interneurons?"
            }
          ],
          "context": "The postnatal functions of the Dlx1&2 transcription factors in cortical interneurons (CINs) are unknown. Here, using conditional Dlx1, Dlx2, and Dlx1&2 knockouts (CKOs), we defined their roles in specific CINs. The CKOs had dendritic, synaptic, and survival defects, affecting even PV+ CINs. We provide evidence that DLX2 directly drives Gad1, Gad2, and Vgat expression, and show that mutants had reduced mIPSC amplitude. In addition, the mutants formed fewer GABAergic synapses on excitatory neurons and had reduced mIPSC frequency. Furthermore, Dlx1/2 CKO had hypoplastic dendrites, fewer excitatory synapses, and reduced excitatory input. We provide evidence that some of these phenotypes were due to reduced expression of GRIN2B (a subunit of the NMDA receptor), a high confidence Autism gene. Thus, Dlx1&2 coordinate key components of CIN postnatal development by promoting their excitability, inhibitory output, and survival."
        },
        {
          "qas": [
            {
              "id": "5a68f633b750ff4455000019_001",
              "question": "Is creatinine assessment included in the MELD score?"
            }
          ],
          "context": "Model For End-Stage Liver Disease (MELD) scores were calculated as 3.78\u00d7ln[TB]\u00a0+\u00a011.2\u00d7ln[INR]\u00a0+\u00a09.57\u00d7ln[creatinine]\u00a0+\u00a06.43. "
        },
        {
          "qas": [
            {
              "id": "5a68f633b750ff4455000019_002",
              "question": "Is creatinine assessment included in the MELD score?"
            }
          ],
          "context": "A corrected creatinine was derived from the mGFR after application of the Modification of Diet in Renal Disease formula. Subsequently, a corrected MELD was calculated and compared with the conventionally calculated MELD."
        },
        {
          "qas": [
            {
              "id": "5a68f633b750ff4455000019_003",
              "question": "Is creatinine assessment included in the MELD score?"
            }
          ],
          "context": "Among patients with MELD score>35, a new prognostic model based on serum creatinine, need for hemodialysis and moderate ascites could identify the sickest one."
        },
        {
          "qas": [
            {
              "id": "5a68f633b750ff4455000019_004",
              "question": "Is creatinine assessment included in the MELD score?"
            }
          ],
          "context": "Patient risk factors evaluated include age, INR (international normalized ratio), creatinine, bilirubin, and MELD score (Model for End-of-stage Liver Disease). "
        },
        {
          "qas": [
            {
              "id": "5a68f633b750ff4455000019_005",
              "question": "Is creatinine assessment included in the MELD score?"
            }
          ],
          "context": "Limited comparability of creatinine assays in patients with liver cirrhosis and their impact on the MELD score."
        },
        {
          "qas": [
            {
              "id": "5a68f633b750ff4455000019_006",
              "question": "Is creatinine assessment included in the MELD score?"
            }
          ],
          "context": "The model of end-stage liver disease (MELD) score is used for this purpose in most countries and incorporates bilirubin, International Normalized ratio, and creatinine. "
        },
        {
          "qas": [
            {
              "id": "5a68f633b750ff4455000019_007",
              "question": "Is creatinine assessment included in the MELD score?"
            }
          ],
          "context": "The MELD score was calculated using international normalized ratio, serum billirubin and creatinine."
        },
        {
          "qas": [
            {
              "id": "5a68f633b750ff4455000019_008",
              "question": "Is creatinine assessment included in the MELD score?"
            }
          ],
          "context": "Regression analysis identified high creatinine and INR, but not bilirubin, as the MELD components predicting negative outcomes with ELAD. "
        },
        {
          "qas": [
            {
              "id": "5a79d195faa1ab7d2e00000e_001",
              "question": "Is celiac disease caused by gliadin-induced transglutaminase-2 (TG2)-dependent events ?"
            }
          ],
          "context": "Type 2 transglutaminase (TG2) has an important pathogenic role in celiac disease (CD), an inflammatory intestinal disease that is caused by the ingestion of gluten-containing cereals. "
        },
        {
          "qas": [
            {
              "id": "5a79d195faa1ab7d2e00000e_002",
              "question": "Is celiac disease caused by gliadin-induced transglutaminase-2 (TG2)-dependent events ?"
            }
          ],
          "context": "Celiac disease (CD) is a frequent inflammatory intestinal disease, with a genetic background, caused by gliadin-containing food. "
        },
        {
          "qas": [
            {
              "id": "5a79d195faa1ab7d2e00000e_003",
              "question": "Is celiac disease caused by gliadin-induced transglutaminase-2 (TG2)-dependent events ?"
            }
          ],
          "context": "Celiac disease (CD) is an autoimmune enteropathy initiated and sustained by the ingestion of gluten in genetically susceptible individuals. It is caused by a dysregulated immune response toward both dietary antigens, the gluten proteins of wheat, rye, and barley, and autoantigens, the enzyme tissue transglutaminase (TG2)"
        },
        {
          "qas": [
            {
              "id": "5a79d25dfaa1ab7d2e00000f_001",
              "question": "Does wheat belongs to the genus Avena, yes or no?"
            }
          ],
          "context": "oat seedlings (Avena sativa)"
        },
        {
          "qas": [
            {
              "id": "5a79d25dfaa1ab7d2e00000f_002",
              "question": "Does wheat belongs to the genus Avena, yes or no?"
            }
          ],
          "context": "wild green-oat (Avena sativa) "
        },
        {
          "qas": [
            {
              "id": "5a79d25dfaa1ab7d2e00000f_003",
              "question": "Does wheat belongs to the genus Avena, yes or no?"
            }
          ],
          "context": " Oat (Avena sativa L.)"
        },
        {
          "qas": [
            {
              "id": "5a79d25dfaa1ab7d2e00000f_004",
              "question": "Does wheat belongs to the genus Avena, yes or no?"
            }
          ],
          "context": "Oat (Avena sativa L.)"
        },
        {
          "qas": [
            {
              "id": "5a6d2558b750ff4455000036_001",
              "question": "Does Uc.160 promote cancer?"
            }
          ],
          "context": "We previously discovered the downregulation of T-UCR expression in gastric cancer (GC), indicating that T-UCRs could play an important role in GC biology. Uc.160+, a T-UCR reported to be downregulated in human cancer, has not been examined in GC.METHODS: We analyzed the expression pattern of Uc.160+ in nonneoplastic and tumor tissues of the stomach by using uantitative reverse transcription polymerase chain reaction (qRT-PCR) and in situ hybridization (ISH), specifically focusing on the mechanism of transcriptional regulation and target genes that are regulated by T-UCRs. We also attempted to determine the effect of Uc.160+ expression on biological features of GC cell lines by Western blotting.RESULTS: On the basis of the qRT-PCR and ISH results, Uc.160+ expression in adenoma and GC tissues was clearly downregulated compared with that in nonneoplastic mucosa tissues of the stomach. Cancer-specific DNA methylation in the promoter region of Uc.160 was observed by bisulfite genomic DNA sequencing analysis. The effect of DNA methylation on Uc.160+ expression was further confirmed by reporter gene assay. We also revealed that Uc.160+ inhibited the phosphorylation of Akt by regulating phosphatase and tensin homolog (PTEN) expression.CONCLUSIONS: These results indicate that Uc.160+ could possibly have a tumor suppressive role in GC."
        },
        {
          "qas": [
            {
              "id": "5a69031bb750ff445500001e_001",
              "question": "Can doxycycline cause photosensitivity?"
            }
          ],
          "context": "Phototoxicity of Doxycycline: A Systematic Review on Clinical Manifestations, Frequency, Cofactors, and Prevention."
        },
        {
          "qas": [
            {
              "id": "5a69031bb750ff445500001e_002",
              "question": "Can doxycycline cause photosensitivity?"
            }
          ],
          "context": "BACKGROUND: One of the most important dermatologic side effects of doxycycline is photosensitivity. "
        },
        {
          "qas": [
            {
              "id": "5a69031bb750ff445500001e_003",
              "question": "Can doxycycline cause photosensitivity?"
            }
          ],
          "context": "While there are many publications on the phototoxicity of tetracyclines in general, only a few exist focusing on doxycycline. "
        },
        {
          "qas": [
            {
              "id": "5a69031bb750ff445500001e_004",
              "question": "Can doxycycline cause photosensitivity?"
            }
          ],
          "context": "Clinical symptoms vary from light sunburn-like sensation (burning, erythema) to large-area photodermatitis. "
        },
        {
          "qas": [
            {
              "id": "5a69031bb750ff445500001e_005",
              "question": "Can doxycycline cause photosensitivity?"
            }
          ],
          "context": "CONCLUSION: Evidence base must be improved for giving advice on appropriate prevention measures to travelers taking doxycycline and having a risk of significant sun exposure."
        },
        {
          "qas": [
            {
              "id": "5a69031bb750ff445500001e_006",
              "question": "Can doxycycline cause photosensitivity?"
            }
          ],
          "context": "Based on the available evidence, our best estimates of absolute effect for mefloquine versus doxycyline were: 2% versus 2% for discontinuation, 12% versus 3% for insomnia, 31% versus 3% for abnormal dreams, 18% versus 1% for anxiety, 11% versus 1% for depressed mood, 4% versus 14% for dyspepsia, 2% versus 19% for photosensitivity, 1% versus 5% for vomiting, and 2% versus 16% for vaginal thrush."
        },
        {
          "qas": [
            {
              "id": "5a69031bb750ff445500001e_007",
              "question": "Can doxycycline cause photosensitivity?"
            }
          ],
          "context": "Many drugs are responsible for this phototoxic reaction, especially tetracyclines, psoralens, chloramphenicol, non-steroidal anti-inflammatory drugs, fluoroquinolones, and, rarely, doxycycline. "
        },
        {
          "qas": [
            {
              "id": "5a69031bb750ff445500001e_008",
              "question": "Can doxycycline cause photosensitivity?"
            }
          ],
          "context": "OBJECTIVES: Many patients undergoing long-term doxycycline treatment do not regularly take their treatment because of photosensitivity."
        },
        {
          "qas": [
            {
              "id": "5a69031bb750ff445500001e_009",
              "question": "Can doxycycline cause photosensitivity?"
            }
          ],
          "context": "Modulation of Melanogenesis and Antioxidant Status of Melanocytes in Response to Phototoxic Action of Doxycycline."
        },
        {
          "qas": [
            {
              "id": "5a69031bb750ff445500001e_010",
              "question": "Can doxycycline cause photosensitivity?"
            }
          ],
          "context": "Doxycycline is a commonly used tetracycline antibiotic showing the broad spectrum of antibacterial action. However, the use of this antibiotic is often connected with the risk of phototoxic reactions that lead to various skin disorders."
        },
        {
          "qas": [
            {
              "id": "5a69031bb750ff445500001e_011",
              "question": "Can doxycycline cause photosensitivity?"
            }
          ],
          "context": "The results obtained in vitro may explain the mechanisms of phototoxic reactions that occur in normal human epidermal melanocytes in vivo after exposure of skin to doxycycline and UVA radiation."
        },
        {
          "qas": [
            {
              "id": "5a6e21b4b750ff445500003a_001",
              "question": "Are paralog genes co-regulated?"
            }
          ],
          "context": "Co-regulation of paralog genes in the three-dimensional chromatin architecture."
        },
        {
          "qas": [
            {
              "id": "5a6e21b4b750ff445500003a_002",
              "question": "Are paralog genes co-regulated?"
            }
          ],
          "context": "Consequently, paralogs show correlation in gene expression whereby the mechanisms of co-regulation remain unclear. In eukaryotes, genes are regulated in part by distal enhancer elements through looping interactions with gene promoters. These looping interactions can be measured by genome-wide chromatin conformation capture (Hi-C) experiments, which revealed self-interacting regions called topologically associating domains (TADs). We hypothesize that paralogs share common regulatory mechanisms to enable coordinated expression according to TADs. To test this hypothesis, we integrated paralogy annotations with human gene expression data in diverse tissues, genome-wide enhancer-promoter associations and Hi-C experiments in human, mouse and dog genomes. We show that paralog gene pairs are enriched for co-localization in the same TAD, share more often common enhancer elements than expected and have increased contact frequencies over large genomic distances. Combined, our results indicate that paralogs share common regulatory mechanisms and cluster not only in the linear genome but also in the three-dimensional chromatin architecture. This enables concerted expression of paralogs over diverse cell-types and indicate evolutionary constraints in functional genome organization."
        },
        {
          "qas": [
            {
              "id": "5a8714e261bb38fb24000005_001",
              "question": "Is polyadenylation a process that stabilizes a protein by adding a string of Adenosine residues to the end of the molecule?"
            }
          ],
          "context": "The addition of poly(A) tails to eukaryotic nuclear mRNAs promotes their stability, export to the cytoplasm and translation. "
        },
        {
          "qas": [
            {
              "id": "5a8714e261bb38fb24000005_002",
              "question": "Is polyadenylation a process that stabilizes a protein by adding a string of Adenosine residues to the end of the molecule?"
            }
          ],
          "context": "Most eukaryotic genes express mRNAs with alternative polyadenylation sites at their 3' ends"
        },
        {
          "qas": [
            {
              "id": "5a6f829eb750ff4455000054_001",
              "question": "Can multiple myeloma patients develop hyperviscosity syndrome?"
            }
          ],
          "context": "Multiple myeloma (MM) is an immedicable malignancy of the human plasma cells producing abnormal antibodies (also referred to as paraproteins) leading to kidney problems and hyperviscosity syndrome. "
        },
        {
          "qas": [
            {
              "id": "5a6f829eb750ff4455000054_002",
              "question": "Can multiple myeloma patients develop hyperviscosity syndrome?"
            }
          ],
          "context": "This skin condition may be observed in patients with the following condtions, such as primary polycythemic hyperviscosity (polycythemia, thrombocytemia) treated with hydroxyurea, primary plasma hyperviscosity (multiple myeloma, cryoglobulinemia, cryofibrinogenemia, dysfibrinogenemia, and connective tissue diseases), primary sclerocythemic hyperviscosity (hereditary spherocytosis, thalassemia, and sickle cell disease). "
        },
        {
          "qas": [
            {
              "id": "5a6f829eb750ff4455000054_003",
              "question": "Can multiple myeloma patients develop hyperviscosity syndrome?"
            }
          ],
          "context": " A 73-year-old woman with known MM who received little treatment for several years, presented secondary to dysarthria and at first was thought to have hyperviscosity syndrome. "
        },
        {
          "qas": [
            {
              "id": "5a6f829eb750ff4455000054_004",
              "question": "Can multiple myeloma patients develop hyperviscosity syndrome?"
            }
          ],
          "context": " After a comprehensive evaluation ruled out common causes of acute renal failure, the patient underwent testing with a bone survey, urine protein electrophoresis (UPEP), serum protein electrophoresis (SPEP), and immunoelectrophoresis for suspected plasma cell dyscrasia and received plasmapheresis for hyperviscosity syndrome and nephrotoxicity, which resulted in improved renal function. Lab results showed monoclonal gammopathy, elevated serum free light chains, and Bence Jones protein in the urine with a follow-up bone marrow biopsy indicating plasma cell dyscrasia. The patient received a diagnosis of multiple myeloma (MM) and was started on chemotherapy and immunosuppression. "
        },
        {
          "qas": [
            {
              "id": "5a6f829eb750ff4455000054_005",
              "question": "Can multiple myeloma patients develop hyperviscosity syndrome?"
            }
          ],
          "context": "Plasmapheresis (PE) is recommended for patients with hyperviscosity syndrome or cast nephropathy presented with AKI, which may help to increase the dialysis-independency."
        },
        {
          "qas": [
            {
              "id": "5a6f829eb750ff4455000054_006",
              "question": "Can multiple myeloma patients develop hyperviscosity syndrome?"
            }
          ],
          "context": "Multiple myeloma is a neoplastic plasma-cell disorder resulting from malignant plasma cells in the bone marrow. It can cause a hyperviscosity syndrome secondary to the paraproteinaemia associated with the disease. The increased hyperviscosity can lead to retinal vein occlusions and other ocular problems that may challenge clinicians. "
        },
        {
          "qas": [
            {
              "id": "5a6f829eb750ff4455000054_007",
              "question": "Can multiple myeloma patients develop hyperviscosity syndrome?"
            }
          ],
          "context": "Etiologies are various but symptomatic hyperviscosity is more common in Waldenstr\u00f6m's macroglobulinemia and multiple myeloma. "
        },
        {
          "qas": [
            {
              "id": "5a6f829eb750ff4455000054_008",
              "question": "Can multiple myeloma patients develop hyperviscosity syndrome?"
            }
          ],
          "context": "Double filtration plasmapheresis in a dog with multiple myeloma and hyperviscosity syndrome."
        },
        {
          "qas": [
            {
              "id": "5a6f829eb750ff4455000054_009",
              "question": "Can multiple myeloma patients develop hyperviscosity syndrome?"
            }
          ],
          "context": "A 12 year old, 38 kg, mix-breed, intact male dog presented with a 20 day history of clinical signs consistent with hyperviscosity syndrome secondary to multiple myeloma. "
        },
        {
          "qas": [
            {
              "id": "5a6f829eb750ff4455000054_010",
              "question": "Can multiple myeloma patients develop hyperviscosity syndrome?"
            }
          ],
          "context": "The present study reported for the first time the use of double filtration plasmapheresis to reduce clinical signs of hyperviscosity syndrome in a dog with multiple myeloma."
        },
        {
          "qas": [
            {
              "id": "5a6f829eb750ff4455000054_011",
              "question": "Can multiple myeloma patients develop hyperviscosity syndrome?"
            }
          ],
          "context": "An otherwise healthy young man presents with bilateral CRVO as the first sign of hyperviscosity syndrome in the setting of new multiple myeloma."
        },
        {
          "qas": [
            {
              "id": "5a6f829eb750ff4455000054_012",
              "question": "Can multiple myeloma patients develop hyperviscosity syndrome?"
            }
          ],
          "context": " In haematology the most common indication for plasmapheresis is the supportive treatment of multiple myeloma. The procedure is performed in patients with high protein levels endangered with hyperviscosity syndrome."
        },
        {
          "qas": [
            {
              "id": "5a6f87c5b750ff4455000056_001",
              "question": "Are patients with Sjogren syndrome at increased risk for lymphoma?"
            }
          ],
          "context": "The heightened risk of non-Hodgkin lymphoma (NHL) development in primary Sjogren syndrome (SS) is well established."
        },
        {
          "qas": [
            {
              "id": "5a6f87c5b750ff4455000056_002",
              "question": "Are patients with Sjogren syndrome at increased risk for lymphoma?"
            }
          ],
          "context": "Primary Diffuse Large B-Cell Lymphoma of the Liver in a Patient with Sjogren Syndrome."
        },
        {
          "qas": [
            {
              "id": "5a6f87c5b750ff4455000056_003",
              "question": "Are patients with Sjogren syndrome at increased risk for lymphoma?"
            }
          ],
          "context": "Immunohistochemical and molecular features of the tumors allowed diagnosis of diffuse large B-cell lymphoma (DLBCL). "
        },
        {
          "qas": [
            {
              "id": "5a6f87c5b750ff4455000056_004",
              "question": "Are patients with Sjogren syndrome at increased risk for lymphoma?"
            }
          ],
          "context": "To our knowledge, the patient described here represents the first reported case of DLBCL with primary liver involvement in SS."
        },
        {
          "qas": [
            {
              "id": "5a6f87c5b750ff4455000056_005",
              "question": "Are patients with Sjogren syndrome at increased risk for lymphoma?"
            }
          ],
          "context": "Rituximab is also effective in the treatment of SS-associated (extrasalivary) lymphomas, although the therapeutic response in salivary lymphoma is poorer."
        },
        {
          "qas": [
            {
              "id": "5a6f87c5b750ff4455000056_006",
              "question": "Are patients with Sjogren syndrome at increased risk for lymphoma?"
            }
          ],
          "context": "Rituximab treatment for Sjogren syndrome-associated non-Hodgkin's lymphoma: case series."
        },
        {
          "qas": [
            {
              "id": "5a6f87c5b750ff4455000056_007",
              "question": "Are patients with Sjogren syndrome at increased risk for lymphoma?"
            }
          ],
          "context": "Five per cent of patients with primary Sjogren's syndrome (pSS) develop malignant non-Hodgkin's lymphoma (NHL), usually of the mucosa-associated lymphoid tissue (MALT) and most frequently located in the major salivary glands. "
        },
        {
          "qas": [
            {
              "id": "5a6f87c5b750ff4455000056_008",
              "question": "Are patients with Sjogren syndrome at increased risk for lymphoma?"
            }
          ],
          "context": "[A case of Sjogren syndrome coexistent with MALT lymphoma occurring along the parotid gland and trachea]."
        },
        {
          "qas": [
            {
              "id": "5a6f87c5b750ff4455000056_009",
              "question": "Are patients with Sjogren syndrome at increased risk for lymphoma?"
            }
          ],
          "context": "Both histological examinations revealed MALT-type marginal zone B-cell lymphoma. "
        },
        {
          "qas": [
            {
              "id": "5a6f87c5b750ff4455000056_010",
              "question": "Are patients with Sjogren syndrome at increased risk for lymphoma?"
            }
          ],
          "context": "In the majority of patients, it is a late event and frequently associated with systemic disease or risk factors for lymphoma development."
        },
        {
          "qas": [
            {
              "id": "5a6f87c5b750ff4455000056_011",
              "question": "Are patients with Sjogren syndrome at increased risk for lymphoma?"
            }
          ],
          "context": "The incidence of lymphoma is higher in patients with Sj\u00f6gren's syndrome than in the general population."
        },
        {
          "qas": [
            {
              "id": "5a6f87c5b750ff4455000056_012",
              "question": "Are patients with Sjogren syndrome at increased risk for lymphoma?"
            }
          ],
          "context": "SS is strongly linked to lymphoma while lupus is not. "
        },
        {
          "qas": [
            {
              "id": "5a6e3fe3b750ff4455000044_001",
              "question": "Does the human lncRNA LINC-PINT promote tumorigenesis?"
            }
          ],
          "context": "The human lncRNA LINC-PINT inhibits tumor cell invasion through a highly conserved sequence element."
        },
        {
          "qas": [
            {
              "id": "5a6e3fe3b750ff4455000044_002",
              "question": "Does the human lncRNA LINC-PINT promote tumorigenesis?"
            }
          ],
          "context": "Here we characterize the function of the p53-regulated human lncRNA LINC-PINT in cancer. We find that LINC-PINT is downregulated in multiple types of cancer and acts as a tumor suppressor lncRNA by reducing the invasive phenotype of cancer cells. A cross-species analysis identifies a highly conserved sequence element in LINC-PINT that is essential for its function. This sequence mediates a specific interaction with PRC2, necessary for the LINC-PINT-dependent repression of a pro-invasion signature of genes regulated by the transcription factor EGR1."
        },
        {
          "qas": [
            {
              "id": "5a6f922fb750ff4455000059_001",
              "question": "Can canagliflozin cause euglycemic diabetic ketoacidosis?"
            }
          ],
          "context": "CASE REPORT: We present a case of a 57-year-old woman with type 2 diabetes mellitus taking a combination of canagliflozin and metformin who presented with progressive altered mental status over the previous 2\u00a0days. Her work-up demonstrated a metabolic acidosis with an anion gap of 38 and a venous serum pH of 7.08. The serum glucose was 168\u00a0mg/dL. The urinalysis showed glucose>500\u00a0mg/dL and ketones of 80\u00a0mg/dL. Further evaluation demonstrated an elevated serum osmolality of 319 mOsm/kg and an acetone concentration of 93\u00a0mg/dL. She was treated with intravenous insulin and fluids, and the metabolic abnormalities and her altered mental status resolved within 36\u00a0h. This was the first episode of diabetic ketoacidosis (DKA) for this patient. WHY SHOULD AN EMERGENCY PHYSICIAN BE AWARE OF THIS?: Diabetic patients on SGLT2 inhibitor medications are at risk for ketoacidosis. Due to the renal glucose-wasting properties of these drugs, they may present with ketoacidosis with only mild elevations in serum glucose, potentially complicating the diagnosis. "
        },
        {
          "qas": [
            {
              "id": "5a6f922fb750ff4455000059_002",
              "question": "Can canagliflozin cause euglycemic diabetic ketoacidosis?"
            }
          ],
          "context": "Euglycemic Diabetic Ketoacidosis with Persistent Diuresis Treated with Canagliflozin."
        },
        {
          "qas": [
            {
              "id": "5a6f922fb750ff4455000059_003",
              "question": "Can canagliflozin cause euglycemic diabetic ketoacidosis?"
            }
          ],
          "context": "We herein report the case of a 27-year-old Asian woman with type 2 diabetes who was treated with a sodium-glucose cotransporter 2 (SGLT2) inhibitor (canagliflozin) who developed euglycemic diabetic ketoacidosis and persistent diuresis in the absence of hyperglycemia."
        },
        {
          "qas": [
            {
              "id": "5a6f922fb750ff4455000059_004",
              "question": "Can canagliflozin cause euglycemic diabetic ketoacidosis?"
            }
          ],
          "context": "Canagliflozin raised the risk of amputations and the rate of fractures in the CANVAS trial, although more data are necessary before drawing definite conclusions. The risk of euglycemic diabetic ketoacidosis seems to be minimal when the drugs are prescribed properly."
        },
        {
          "qas": [
            {
              "id": "5a6f922fb750ff4455000059_005",
              "question": "Can canagliflozin cause euglycemic diabetic ketoacidosis?"
            }
          ],
          "context": "Severe Ketoacidosis Associated with Canagliflozin (Invokana): A Safety Concern."
        },
        {
          "qas": [
            {
              "id": "5a6f922fb750ff4455000059_006",
              "question": "Can canagliflozin cause euglycemic diabetic ketoacidosis?"
            }
          ],
          "context": " However, some serious side effects, including severe anion gap metabolic acidosis and euglycemic diabetic ketoacidosis (DKA), have been reported. "
        },
        {
          "qas": [
            {
              "id": "5a6f922fb750ff4455000059_007",
              "question": "Can canagliflozin cause euglycemic diabetic ketoacidosis?"
            }
          ],
          "context": "At present, the Food and Drug Administration (FDA) has only approved three medications (canagliflozin, dapagliflozin and empagliflozin) in this drug class for the management of Type 2 diabetes. In May 2015, the FDA issued a warning of ketoacidosis with use of this drug class."
        },
        {
          "qas": [
            {
              "id": "5a6f922fb750ff4455000059_008",
              "question": "Can canagliflozin cause euglycemic diabetic ketoacidosis?"
            }
          ],
          "context": "We present a case of euglycemic diabetic ketoacidosis secondary to canagliflozin in a type 2 diabetic patient."
        },
        {
          "qas": [
            {
              "id": "5a6f922fb750ff4455000059_009",
              "question": "Can canagliflozin cause euglycemic diabetic ketoacidosis?"
            }
          ],
          "context": "Nonconvulsive Status Epilepticus in Elderly Patients Receiving SSRIs; Euglycemic Diabetic Ketoacidosis Associated with Canagliflozin Use in a Type 1 Diabetic Patient; Duloxetine-Induced Galactorrhea; Canagliflozin-Associated Severe Hypercalcemia and Hypernatremia; Vemurafenib-Induced Fanconi Syndrome."
        },
        {
          "qas": [
            {
              "id": "5a6f922fb750ff4455000059_010",
              "question": "Can canagliflozin cause euglycemic diabetic ketoacidosis?"
            }
          ],
          "context": "Euglycemic Diabetic Ketoacidosis in a 27 year-old female patient with type-1-Diabetes treated with sodium-glucose cotransporter-2 (SGLT2) inhibitor Canagliflozin."
        },
        {
          "qas": [
            {
              "id": "5a6f922fb750ff4455000059_011",
              "question": "Can canagliflozin cause euglycemic diabetic ketoacidosis?"
            }
          ],
          "context": "We are reporting a timely case of atypical euglycemic diabetic ketoacidosis in a type 1 diabetic patient treated with sodium-glucose cotransporter-2 (SGLT-2) inhibitor canagliflozin."
        },
        {
          "qas": [
            {
              "id": "5a6f922fb750ff4455000059_012",
              "question": "Can canagliflozin cause euglycemic diabetic ketoacidosis?"
            }
          ],
          "context": "Euglycemic ketoacidosis did not recur in our patient after discontinuing canagliflozin. "
        },
        {
          "qas": [
            {
              "id": "5a6f922fb750ff4455000059_013",
              "question": "Can canagliflozin cause euglycemic diabetic ketoacidosis?"
            }
          ],
          "context": "Euglycemic Diabetic Ketoacidosis With Prolonged Glucosuria Associated With the Sodium-Glucose Cotransporter-2 Canagliflozin."
        },
        {
          "qas": [
            {
              "id": "5a6f922fb750ff4455000059_014",
              "question": "Can canagliflozin cause euglycemic diabetic ketoacidosis?"
            }
          ],
          "context": "In this article, we present a case of a 50-year-old woman with type 2 diabetes who developed euglycemic DKA after initiating therapy with canagliflozin. "
        },
        {
          "qas": [
            {
              "id": "5a6f922fb750ff4455000059_015",
              "question": "Can canagliflozin cause euglycemic diabetic ketoacidosis?"
            }
          ],
          "context": "SGLT2 inhibitors such as canagliflozin may predispose patients not only to diabetic ketoacidosis but also to prolonged glucosuria."
        },
        {
          "qas": [
            {
              "id": "5a6e49a4b750ff445500004b_001",
              "question": "Is LDB1-mediated enhancer looping dependent on cohesin?"
            }
          ],
          "context": "LDB1-mediated enhancer looping can be established independent of mediator and cohesin."
        },
        {
          "qas": [
            {
              "id": "5a6e49a4b750ff445500004b_002",
              "question": "Is LDB1-mediated enhancer looping dependent on cohesin?"
            }
          ],
          "context": "Moreover, ENCODE data and our chromatin immunoprecipitation results indicate that cohesin is almost completely absent from validated and predicted LDB1-regulated erythroid enhancer-gene pairs. Thus, lineage specific factors largely mediate enhancer-promoter looping in erythroid cells independent of mediator and cohesin."
        },
        {
          "qas": [
            {
              "id": "5a6e4b72b750ff445500004c_001",
              "question": "Is there any link between ERCC1-XPF and cohesin?"
            }
          ],
          "context": "ERCC1-XPF cooperates with CTCF and cohesin to\u00a0facilitate the developmental silencing of imprinted\u00a0genes."
        },
        {
          "qas": [
            {
              "id": "5a6e4b72b750ff445500004c_002",
              "question": "Is there any link between ERCC1-XPF and cohesin?"
            }
          ],
          "context": "Using an in vivo biotinylation tagging approach in mice, we show that the nucleotide excision repair (NER) structure-specific endonuclease ERCC1-XPF complex interacts with the insulator binding protein CTCF, the cohesin subunits SMC1A and SMC3 and with MBD2; the factors co-localize with ATRX at the promoters and control regions (ICRs) of imprinted genes during postnatal hepatic development. Loss of Ercc1 or exposure to MMC triggers the localization of CTCF to heterochromatin, the dissociation of the CTCF-cohesin complex and ATRX from promoters and ICRs, altered histone marks and\u00a0the aberrant developmental expression of imprinted genes without altering DNA methylation. We propose that ERCC1-XPF cooperates with CTCF and cohesin to facilitate the developmental silencing of imprinted genes and that persistent DNA damage triggers chromatin changes that affect gene expression programs associated with NER disorders."
        },
        {
          "qas": [
            {
              "id": "5a70d43b99e2c3af26000003_001",
              "question": "Does prolactinoma increase osteoporosis risk?"
            }
          ],
          "context": "Prolactinoma: A Massive Effect on Bone Mineral Density in a Young Patient."
        },
        {
          "qas": [
            {
              "id": "5a70d43b99e2c3af26000003_002",
              "question": "Does prolactinoma increase osteoporosis risk?"
            }
          ],
          "context": "Osteoporosis has been noted to be an issue in postmenopausal women with prolactinomas. This case shows a similar impact on bone health in a young male resulting in low bone mineral density for age based on Z-score. This case report highlights the possible mechanisms for the bone loss in the setting of prolactinoma and the need for assessing bone health in such patients."
        },
        {
          "qas": [
            {
              "id": "5a70d43b99e2c3af26000003_003",
              "question": "Does prolactinoma increase osteoporosis risk?"
            }
          ],
          "context": " Hyperprolactinaemia related to prolactinoma significantly (more than functional hyperprolactiaemia) increases the risk of osteopenia, osteoporosis and bone fractures. "
        },
        {
          "qas": [
            {
              "id": "5a70d43b99e2c3af26000003_004",
              "question": "Does prolactinoma increase osteoporosis risk?"
            }
          ],
          "context": "Prolactinomas are the most common type of functional pituitary tumor. Effective hyperprolactinemia treatment is of great importance, due to its potential deleterious effects including infertility, gonadal dysfunction and osteoporosis. "
        },
        {
          "qas": [
            {
              "id": "5a70d43b99e2c3af26000003_005",
              "question": "Does prolactinoma increase osteoporosis risk?"
            }
          ],
          "context": "Prolactinomas cause hypogonadism, infertility, osteoporosis, and tumor mass effects, and are the most common type of neuroendocrine tumor."
        },
        {
          "qas": [
            {
              "id": "5a70d43b99e2c3af26000003_006",
              "question": "Does prolactinoma increase osteoporosis risk?"
            }
          ],
          "context": "We present a 22-year-old man with multiple osteoporotic fractures associated with prolactinoma despite the use of teriparatide for 18 months. We emphasize and highlight the importance of hyperprolactinemia and fractures caused by high prolactin levels."
        },
        {
          "qas": [
            {
              "id": "5a70d43b99e2c3af26000003_007",
              "question": "Does prolactinoma increase osteoporosis risk?"
            }
          ],
          "context": "OBJECTIVE: Patients with prolactinoma seem to be at high risk for osteopenia. "
        },
        {
          "qas": [
            {
              "id": "5a70d43b99e2c3af26000003_008",
              "question": "Does prolactinoma increase osteoporosis risk?"
            }
          ],
          "context": "RESULTS: Compared to the matched controls, BMD of patients with prolactinoma or craniopharyngioma significantly decreased. "
        },
        {
          "qas": [
            {
              "id": "5a70d43b99e2c3af26000003_009",
              "question": "Does prolactinoma increase osteoporosis risk?"
            }
          ],
          "context": "CONCLUSION: In the premenopausal women, patients with prolactinoma or craniopharyngioma are often accompanied with osteopenia or osteoporosis, and disease duration and hypogonadism are the risk factors of bone loss in prolactinoma."
        },
        {
          "qas": [
            {
              "id": "5a70d43b99e2c3af26000003_010",
              "question": "Does prolactinoma increase osteoporosis risk?"
            }
          ],
          "context": "Data on osteoporotic fractures in hyperprolactinemia are limited. An increased prevalence of radiological vertebral fractures was recently observed in women with prolactin (PRL)-secreting adenoma, whereas it is unknown whether this observation may reflect a more general increased risk of fractures in this disease and whether the prevalence of fractures in males is affected by gonadal status."
        },
        {
          "qas": [
            {
              "id": "5a70d43b99e2c3af26000003_011",
              "question": "Does prolactinoma increase osteoporosis risk?"
            }
          ],
          "context": "Prolactinoma presenting as chronic anaemia with osteoporosis: a case report."
        },
        {
          "qas": [
            {
              "id": "5a70d43b99e2c3af26000003_012",
              "question": "Does prolactinoma increase osteoporosis risk?"
            }
          ],
          "context": "Six years later, he was evaluated and diagnosed with a prolactinoma and resultant osteoporosis. Prolactinoma in old people may present insidiously with chronic anaemia and osteoporosis with or without sexual dysfunction."
        },
        {
          "qas": [
            {
              "id": "5a70ea8299e2c3af2600000b_001",
              "question": "Does Evolocumab improve cognitive function?"
            }
          ],
          "context": "Conclusions In a randomized trial involving patients who received either evolocumab or placebo in addition to statin therapy, no significant between-group difference in cognitive function was observed over a median of 19 months. "
        },
        {
          "qas": [
            {
              "id": "5a70ea8299e2c3af2600000b_002",
              "question": "Does Evolocumab improve cognitive function?"
            }
          ],
          "context": "Results A total of 1204 patients were followed for a median of 19 months; the mean (\u00b1SD) change from baseline over time in the raw score for the spatial working memory strategy index of executive function (primary end point) was -0.21\u00b12.62 in the evolocumab group and -0.29\u00b12.81 in the placebo group (P<0.001 for noninferiority; P=0.85 for superiority). There were no significant between-group differences in the secondary end points of scores for working memory (change in raw score, -0.52 in the evolocumab group and -0.93 in the placebo group), episodic memory (change in raw score, -1.53 and -1.53, respectively), or psychomotor speed (change in raw score, 5.2 msec and 0.9 msec, respectively). "
        },
        {
          "qas": [
            {
              "id": "5a72284b2dc08e987e000001_001",
              "question": "Can radius fracture cause carpal tunnel syndrome?"
            }
          ],
          "context": "Carpal tunnel syndrome (CTS) after distal radius fractures can present in 3 forms: acute, transient, and delayed."
        },
        {
          "qas": [
            {
              "id": "5a72284b2dc08e987e000001_002",
              "question": "Can radius fracture cause carpal tunnel syndrome?"
            }
          ],
          "context": "Complications were categorized as carpal tunnel syndrome, other sensibility issues, tendon complications including irritation and rupture, deep infections, complex regional pain syndrome and unidentified DRUJ or scapholunar problems."
        },
        {
          "qas": [
            {
              "id": "5a72284b2dc08e987e000001_003",
              "question": "Can radius fracture cause carpal tunnel syndrome?"
            }
          ],
          "context": "The overall complication rate was 14.6% (95% CI 11.8-17.7) including carpal tunnel syndrome or change in sensibility in 5.2% and tendon complications in 4.7%. "
        },
        {
          "qas": [
            {
              "id": "5a72284b2dc08e987e000001_004",
              "question": "Can radius fracture cause carpal tunnel syndrome?"
            }
          ],
          "context": "BACKGROUND: Although median nerve neuropathy and carpal tunnel syndrome (CTS) are known complications of both untreated and acutely treated distal radius fracture, median neuropathy after correction of distal radius malunion is not commonly reported in hand surgery literature. "
        },
        {
          "qas": [
            {
              "id": "5a72284b2dc08e987e000001_005",
              "question": "Can radius fracture cause carpal tunnel syndrome?"
            }
          ],
          "context": "Complications were defined as malunion, carpal tunnel syndrome, complex regional pain syndrome (CRPS), persistent pain, and subjective cosmetic deformity of the wrist."
        },
        {
          "qas": [
            {
              "id": "5a72284b2dc08e987e000001_006",
              "question": "Can radius fracture cause carpal tunnel syndrome?"
            }
          ],
          "context": "Carpal tunnel syndrome is a common complication associated with distal radius fractures."
        },
        {
          "qas": [
            {
              "id": "5a72284b2dc08e987e000001_007",
              "question": "Can radius fracture cause carpal tunnel syndrome?"
            }
          ],
          "context": "The patient also had minor complications of little finger flexor tendon irritation and carpal tunnel syndrome. She underwent implant removal and carpal tunnel release at 8 months."
        },
        {
          "qas": [
            {
              "id": "5a72284b2dc08e987e000001_008",
              "question": "Can radius fracture cause carpal tunnel syndrome?"
            }
          ],
          "context": "Acute multiple flexor tendon injury and carpal tunnel syndrome after open distal radius fracture."
        },
        {
          "qas": [
            {
              "id": "5a75f1f383b0d9ea66000006_001",
              "question": "Can Logic Alignment Free (LAF) be used for bacterial genomes classification?"
            }
          ],
          "context": "LAF: Logic Alignment Free and its application to bacterial genomes classification."
        },
        {
          "qas": [
            {
              "id": "5a75f1f383b0d9ea66000006_002",
              "question": "Can Logic Alignment Free (LAF) be used for bacterial genomes classification?"
            }
          ],
          "context": "In this paper, we present Logic Alignment Free (LAF), a method that combines alignment-free techniques and rule-based classification algorithms in order to assign biological samples to their taxa. This method searches for a minimal subset of k-mers whose relative frequencies are used to build classification models as disjunctive-normal-form logic formulas (if-then rules). We apply LAF successfully to the classification of bacterial genomes to their corresponding taxonomy. In particular, we succeed in obtaining reliable classification at different taxonomic levels by extracting a handful of rules, each one based on the frequency of just few k-mers. State of the art methods to adjust the frequency of k-mers to the character distribution of the underlying genomes have negligible impact on classification performance, suggesting that the signal of each class is strong and that LAF is effective in identifying it."
        },
        {
          "qas": [
            {
              "id": "5a722a052dc08e987e000002_001",
              "question": "Is Marfan syndrome associated with chordal rupture?"
            }
          ],
          "context": "Repair of the mitral valve in children who have Marfan syndrome is especially difficult due to the presence of generalized connective tissue disorder, which may lead to future elongation and rupture of chordae tendineae that were unaffected at the time of mitral valve repair."
        },
        {
          "qas": [
            {
              "id": "5a722a052dc08e987e000002_002",
              "question": "Is Marfan syndrome associated with chordal rupture?"
            }
          ],
          "context": "Mitral regurgitation was caused by annulus dilatation in all patients, by leaflet prolapse in five patients, and by chordal rupture due to endocarditis in two. "
        },
        {
          "qas": [
            {
              "id": "5a722a052dc08e987e000002_003",
              "question": "Is Marfan syndrome associated with chordal rupture?"
            }
          ],
          "context": "Perioperative coronary artery spasm in modified Bentall's operation for annulo-aortic ectasia in Marfan's syndrome. A case report of perioperative chordal rupture of the mitral valve."
        },
        {
          "qas": [
            {
              "id": "5a722a052dc08e987e000002_004",
              "question": "Is Marfan syndrome associated with chordal rupture?"
            }
          ],
          "context": "In a modified Bentall's operation (button technique), perioperative severe coronary artery spasm occurred in spite of the preventive use of nitroglycerin infusion, which resulted in profound ventricular fibrillation and subsequent chordal rupture of the mitral valve with Sellers IV regurgitation."
        },
        {
          "qas": [
            {
              "id": "5a722a052dc08e987e000002_005",
              "question": "Is Marfan syndrome associated with chordal rupture?"
            }
          ],
          "context": "It is worthy to report this case because of rarities such as Marfan's syndrome accompanied by Prinzmetal's variant angina, perioperative coronary artery spasm in modified Bentall's operation, and perioperative chordal rupture of the mitral valve and progression of mitral valve regurgitation. "
        },
        {
          "qas": [
            {
              "id": "5a722a052dc08e987e000002_006",
              "question": "Is Marfan syndrome associated with chordal rupture?"
            }
          ],
          "context": " The four Major Complications- sudden death, infective endocarditis, spontaneous rupture of chordae tendineae, and progressive mitral regurgitation- are examined. Associated Cardiac Diseases, i.e., Marfan's syndrome, ostium secundum atrial septal defect and atherosclerotic coronary artery disease, are discussed, and a section on Treatment deals chiefly with prophylaxis for infective endocarditis and the management of arrhythmias and chest pain. "
        },
        {
          "qas": [
            {
              "id": "5a722a052dc08e987e000002_007",
              "question": "Is Marfan syndrome associated with chordal rupture?"
            }
          ],
          "context": "Acute mitral regurgitation due to chordal rupture in a patient with neonatal Marfan syndrome caused by a deletion in exon 29 of the FBN1 gene."
        }
      ],
      "title": "BioASQ6b"
    }
  ],
  "version": "BioASQ6b"
}